REVENUES (Tables)

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Net Sales from Contracts with Customers by Global Business Unit

The following tables disaggregate our net sales from contracts with customers by Global Business Unit (GBU) between the U.S. and international:

	Three months ended September 30,
							As Restated
	2019						2018
(in millions)	U.S.		International		Total		U.S.		International		Total
Renal Care 1	$	199	$	719	$	918	$	209	$	698	$	907
Medication Delivery 2	461		240		701		418		234		652
Pharmaceuticals 3	223		304		527		240		278		518
Clinical Nutrition 4	80		139		219		80		137		217
Advanced Surgery 5	134		82		216		122		77		199
Acute Therapies 6	44		86		130		41		81		122
Other 7	83		57		140		84		62		146
Total Baxter	$	1,224	$	1,627	$	2,851	$	1,194	$	1,567	$	2,761

	Nine months ended September 30,
							As Restated
	2019						2018
(in millions)	U.S.		International		Total		U.S.		International		Total
Renal Care 1	$	587	$	2,092	$	2,679	$	609	$	2,091	$	2,700
Medication Delivery 2	1,308		716		2,024		1,280		726		2,006
Pharmaceuticals 3	690		885		1,575		745		803		1,548
Clinical Nutrition 4	236		403		639		243		417		660
Advanced Surgery 5	397		249		646		339		246		585
Acute Therapies 6	136		255		391		129		250		379
Other 7	183		186		369		206		182		388
Total Baxter	$	3,537	$	4,786	$	8,323	$	3,551	$	4,715	$	8,266

1 Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.

2 Medication Delivery includes sales of our IV therapies, infusion pumps, administration sets and drug reconstitution devices.

3 Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and

pharmacy compounding services.

4 Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.

5 Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis,

tissue sealing and adhesion prevention.

6 Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies  

focused in the intensive care unit (ICU).

7 Other primarily includes sales of contract manufacturing services from our pharmaceutical partnering business.